Marvel Biosciences Announces Closing of Second Tranche of Private Placement

Core Points - Marvel Biosciences Corp. has successfully closed the second tranche of its non-brokered private placement, raising gross proceeds of $18,750 from the issuance of 150,000 units at a price of$0.125 per unit [1][2] - The proceeds from the offering will be allocated towards drug formulation, toxicology studies, and general working capital [5] - The company has clarified that no finders' fees or warrants were paid to Abinvest Corporation and Abingdon Capital Corp. as previously reported [3] Offering Details - The second tranche of the offering involved the issuance of 150,000 units, each consisting of one common share and one warrant [2] - Finders' fees of $1,312.50 were paid in cash, along with the issuance of 10,500 finder's warrants, which are exercisable at$0.175 per share for two years [2] - The offering is limited to accredited investors and is subject to approval by the TSX Venture Exchange [4] Company Overview - Marvel Biosciences Corp. is a Calgary-based pre-clinical stage pharmaceutical development biotechnology company [7] - The company is developing MB-204, a novel fluorinated derivative of the anti-Parkinson's drug Istradefylline, which may also have applications in treating other neurological diseases [7][9] - The company is exploring the potential of MB-204 in addressing neurodevelopmental disorders such as autism, depression, Alzheimer's Disease, Rett Syndrome, and Fragile X Syndrome [9]